This medicine is called “Typlisome”, which is already accredited in the United States, as it works to teach the immune system to stop attacking the pancreatic insulin products. As a result, the drug delays the need for insulin on average up to 3 years.
Diabetes of the first type is a condition in which the immune system attacks insulin cells, which makes the body unable to regulate the level of sugar in the blood. And when sugar increases or significantly decreases, this can lead to serious health complications, sometimes reaching death, so patients need insulin doses daily.
Hannah Robinson, a dentist and mother of two children Devon, is the first adult in the UK to try Tiplisome in the hope of postponing the progress of the disease. Her disease was found in the early stages during pregnancy, and now it is treating the NHS fund at the Royal University of Devon.
“This medicine gives me great freedom and the opportunity to focus on my health before I begin to manage my life as a person who needs insulin daily. This is not only a matter of food control and glucose levels, but also with great control. I was lucky to become part of this study, which can pave the way for my future treatment. ”
This medicine is provided by a limited number of patients on the basis of each case separately, in anticipation of the possibility of use on a wider scale as part of the national health authority.
Dr. Nick Thomas, a diabetes consultant and a clinical lecturer from the University of Exterior, confirms that “Teblisome is a qualitative shift in the treatment of diabetes of type 1, since it provides treatment aimed at an early stage to change the immune process, which slows down the need for insulin.”
A team of experts in the Royal Devon Hospital and the use of exeter, such as genetics, to determine people who are most at risk of infection, hoping to expand the scale of the drug for declining the disease in more patients.
For his part, Dr. Lucy Chambers, the head of the research association in the United Kingdom, says: “Tiplisome” gives people a rare opportunity in the early stages of the disease to extend their life period without the need for insulin. Despite the fact that it is currently available only in the research environment, we are making every effort to get its license, create national examination programs and equip the national healthcare body to ensure treatment on a large scale.
Professor Richard, consultant and professor at the University of Exterpathies, adds:
“Teblizumba is the first drug capable of laying out type 1 diabetes, but it must be prescribed to a clinical diagnosis. Therefore, it is necessary to develop accurate ways to detect the most vulnerable people. ”
Source: Independent
